Across TCGA pan-cancer cohorts, ARHGAP11A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARHGAP11A data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher ARHGAP11A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGAP11A expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

KIRP, UCEC, and LIHC are the cancer types where ARHGAP11A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	II,III,IV	0.141	0.772	<.001	24	view →
UCEC	DFS	Median	All	0.962	0.622	.011	18	view →
LIHC	DFS	Median	III,IV	0.040	0.361	<.001	6	view →
LUSC	DFS	Median	All	1.000	0.653	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ARHGAP11A tumor-vs-normal RNA expression · all ARHGAP11A data types